Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 8314 results

  1. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

    Technology appraisal guidance
    Discontinued

  2. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued Reference number: GID-TA10437

    Technology appraisal guidance
    Discontinued

  3. Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

    Discontinued Reference number: GID-TA10442

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued Reference number: GID-TA10443

    Technology appraisal guidance
    Discontinued

  5. ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

    Discontinued Reference number: GID-TA10445

    Technology appraisal guidance
    Discontinued

  6. Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]

    Discontinued Reference number: GID-TA10447

    Technology appraisal guidance
    Discontinued

  7. L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]

    Discontinued Reference number: GID-TA10452

    Technology appraisal guidance
    Discontinued

  8. Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

    Discontinued Reference number: GID-TA10464

    Technology appraisal guidance
    Discontinued

  9. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued Reference number: GID-TA10465

    Technology appraisal guidance
    Discontinued

  10. Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

    In development Reference number: GID-TA10467 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]

    Discontinued Reference number: GID-TA10473

    Technology appraisal guidance
    Discontinued

  12. Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]

    In development Reference number: GID-TA11272 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]

    In development Reference number: GID-TA11274 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594

    In development Reference number: GID-TA11310 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Multiple sclerosis (primary-progressive) - fingolimod [ID62]

    Discontinued Reference number: GID-TAG221

    Technology appraisal guidance
    Discontinued